imaware
The leading digital health platform that provides home-based health tests.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 9 % | 244 % | 126 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
imaware is a digital health platform founded in 2017 by Jani Tuomi and Nicholas Olteanu. The company is headquartered in Houston, Texas.
The founders were motivated to start the company after a family member of Tuomi's fell ill from a preventable condition. This experience led to the creation of a platform designed to empower individuals to proactively screen for various health conditions.
imaware operates on a direct-to-consumer business model, providing a range of at-home health tests. These tests cover a wide spectrum of health areas, including men's and women's health, cardiovascular diseases, autoimmune conditions, and allergic diseases. The company's services enable users to monitor their health and screen for conditions from the convenience of their homes. The recent acquisition of Binx Health's consumer testing business has expanded imaware's offerings, particularly in the area of sexually transmitted infection (STI) health screening.
Keywords: at-home testing, digital health, preventative care, health screening, direct-to-consumer healthcare, medical diagnostics, wellness monitoring, consumer health, telemedicine, health-tech